Oral bisphosphonate osteoporosis drugs, which include such Actonel, Boniva, and Fosamax, could be associated with an approximately twofold increased risk of esophageal cancer.
All in all, osteoporosis is a major health risk for nearly 30 million Americans, in large part because many are clueless about how to prevent it.
As a result, osteoporosis has become yet another boon for the pharmaceutical industry. According to a 2010-2025 Osteoporosis World Market Report, the condition generated pharmaceutical revenues of over $12 billion worldwide in 2009.
